Integrating Emerging Clinical Research into the Practical Management of Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
A Continuing Medical Education Activity

OVERVIEW OF ACTIVITY
Non-Hodgkin lymphoma (NHL) comprises a heterogeneous group of lymphoproliferative disorders and is one of the most rapidly evolving fields in hematology and oncology. Published results from ongoing clinical trials lead to the continual emergence of new therapeutic agents and changes in the utilization of existing treatments. To offer optimal patient care — including the option of clinical trial participation — practicing medical oncologists, hematologists and hematology-oncology fellows must be well informed of these advances. This program uses relevant case-based discussions among clinical investigators to assist practicing clinicians with the incorporation of newly published data into optimal treatment algorithms for NHL and chronic lymphocytic leukemia.

LEARNING OBJECTIVES
• Develop an algorithm for the evaluation and treatment of newly diagnosed or relapsed/refractory chronic lymphocytic leukemia.
• Apply the results of emerging research to effectively and safely integrate novel agents and regimens into the management of relapsed/refractory indolent lymphoma.
• Counsel patients with follicular lymphoma about the risks and benefits associated with maintenance therapy.
• Assess the utility of clinical and molecular biomarkers in the selection of first-line therapy for diffuse large B-cell lymphoma (DLBCL).
• Identify investigational agents under evaluation for relapsed/refractory DLBCL.
• Communicate the existing and emerging roles of proteasome inhibitors and IMiDs® to patients with mantle-cell lymphomas.
• Integrate currently available therapeutic strategies into the management of advanced cutaneous T-cell lymphoma.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Research To Practice designates this educational activity for a maximum of 3.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY
This CME activity contains both audio and print components. To receive credit, the participant should review the CME information, listen to the CDs and bonus web-only audio and complete the Post-test and Educational Assessment and Credit Form located in the back of this monograph or on our website at CME.ResearchToPractice.com. This monograph contains edited comments, clinical trial schemas, graphics and references that supplement the audio program. ResearchToPractice.com/HOUJC109 includes access to the web-only audio in addition to an easy-to-use, interactive version of this monograph with links to relevant full-text articles, abstracts, trial information and other web resources indicated here in blue, bold text.

This program is supported by educational grants from Celgene Corporation, Eisai Inc, Genentech BioOncology/Biogen Idec and Millennium Pharmaceuticals Inc.

Last review date: June 2009; Release date: June 2009; Expiration date: June 2010
Integrating Emerging Clinical Research into the Practical Management of Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia — Issue 1, 2009

TOPICS/JOURNAL CLUB PAPERS

3 Chronic Lymphocytic Leukemia (CLL)

6 Follicular Lymphoma

11 Diffuse Large B-Cell Lymphoma (DLBCL)

14 Mantle-Cell Lymphoma

16 Cutaneous T-Cell Lymphoma (CTCL)

18 POST-TEST

19 EDUCATIONAL ASSESSMENT AND CREDIT FORM

www.ResearchToPractice.com
Your online resource for integrated oncology education

The new www.ResearchToPractice.com remains a comprehensive online resource offering numerous interactive capabilities but now offers extended search functionality and easier access to:

- Download audio and print programs
- Sign up for audio Podcasts
- Subscribe to RTP programs
- Search specific topics of interest by specialty and tumor type
- Register for upcoming live CME events
- Watch video proceedings

VISIT TODAY!

If you would like to discontinue your complimentary subscription to Hematologic Oncology Update, please email us at Info@ResearchToPractice.com, call us at (800) 648-8654 or fax us at (305) 377-9998. Please include your full name and address, and we will remove you from the mailing list.
CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Czuczman — Advisory Committee (AC): Amgen Inc, Biogen Idec, Celgene Corporation, Cephalon Inc, Eli Lilly and Company, Novartis Pharmaceuticals Corporation; Lectures: Biogen Idec, Genentech BioOncology. Dr Gregory — AC: Amgen Inc, Novartis Pharmaceuticals Corporation; Speakers Bureau (SB): Cephalon Inc, Genentech BioOncology, GlaxoSmithKline, Millennium Pharmaceuticals Inc. Dr Hagemeister — Research Funding: Novartis Pharmaceuticals Corporation; SB: Amgen Inc, Biogen Idec, Cephalon Inc, Genentech BioOncology, Millennium Pharmaceuticals Inc. Dr Leonard — AC: Celgene Corporation, Cephalon Inc, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Pharmion Corporation, Wyeth; Consulting Agreements (CA): Biogen Idec, Genentech BioOncology, GlaxoSmithKline, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Pharmion Corporation, Wyeth; SB: GlaxoSmithKline, Millennium Pharmaceuticals Inc. Dr Morrison — Data Safety Monitoring Board: Celgene Corporation, Merck and Company Inc; SB: Amgen Inc, Celgene Corporation, Genentech BioOncology, Merck and Company Inc, Pfizer Inc. Dr Moskowitz — AC: Amgen Inc, GlaxoSmithKline; Clinical Trial Support: Celgene Corporation, Eli Lilly and Company, Genentech BioOncology. Dr Rai — Honoraria: Bayer Pharmaceuticals Corporation, Celgene Corporation, Cephalon Inc, Genentech BioOncology, GlaxoSmithKline. Dr Smith — AC: Celgene Corporation; CA: Genentech BioOncology; Paid Research: Pfizer Inc, Wyeth; SB: Biogen Idec, Cephalon Inc, Genentech BioOncology, Millennium Pharmaceuticals Inc.

MODERATOR — Neil Love: Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Centocor Ortho Biotech Services LLC, Cephalon Inc, Eisai Inc, Eli Lilly and Company, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Genzyme Corporation, GlaxoSmithKline, ImClone Systems Incorporated, Merck and Company Inc, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Roche Laboratories Inc, Sanofi-Aventis and Wyeth.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
DR RAI: At ASH 2008 Dr Ferrajoli presented a Phase II trial of front-line therapy with lenalidomide for elderly patients (≥65 years old) with chronic lymphocytic leukemia (CLL).

The dosing of lenalidomide is important. For patients with previously treated CLL, higher doses of lenalidomide were effective (Ferrajoli 2008b; Chanan-Khan 2006). However, when Christine Chen started a study for previously untreated CLL, with a high dose, the first two patients developed tumor lysis syndrome and infection. She therefore restarted the protocol at a dose of 2.5 milligrams (Chen 2008).

Ferrajoli started with a dose of five milligrams and found that for the 43 patients who enrolled, all the toxicities were tolerable. Little tumor flare occurred, and all events were Grade I or II. No tumor lysis syndrome was observed. The 35 patients with evaluable disease had a 54 percent partial response rate (Ferrajoli 2008a; [1.1]).

This is an important observation — that elderly patients with CLL can benefit from front-line therapy with lenalidomide. Because the patients achieved only partial remissions, I believe subsequent trials would involve combinations with lenalidomide as front-line therapy.

DR LOVE: Are those trials ongoing?

DR RAI: The CLL Research Consortium has recently started a trial of rituximab in combination with lenalidomide as front-line therapy for

### 1.1 Lenalidomide as Initial Therapy for Elderly Patients (Older than Age 65) with CLL

“Thirty-five patients are evaluable for response having received treatment for at least 3 months. Nineteen patients achieved a partial response according to the 1996 NCIWG criteria for an overall response rate of 54%, 14 patients (40%) had stable disease and 2 patients (6%) experienced disease progression after 4 and 5 months respectively. Treatment with lenalidomide rapidly reduced the number of circulating lymphocytes: 47% of the patients achieved a blood CR and 38% a blood PR...

In conclusion, our early results indicate that lenalidomide given as continuous therapy at a start dose of 5 mg followed by slow dose escalation is safe and well-tolerated as initial therapy by elderly patients with CLL.”

CR = complete response; PR = partial response

all ages. The University of California, San Diego, has already enrolled eight or nine patients, and they are experiencing impressive responses.

DR MORRISON: This abstract is important in terms of evaluating lenalidomide in the front-line setting, but another way the drug could potentially be used is in the maintenance setting. I believe that lenalidomide will have activity in CLL, but the issue will be at what point it can be best placed to help patients. Also, in the real world setting, in which we have older patients who are frailer and can’t tolerate FCR, are other treatment options available? Lenalidomide might be one of those.

DR RAI: Dr Fischer reported on a Phase II trial of the combination of bendamustine and rituximab for patients who were previously treated with one to three regimens for CLL (Fischer 2008). In vitro data had suggested synergy between bendamustine and rituximab in primary CLL cells, and bendamustine has been approved for CLL.

Patients received 70 mg/m² of bendamustine on days one and two, and 375 mg/m² of rituximab in cycle one and 500 mg/m² from cycle two onward. Of the 81 patients enrolled, 62 were evaluable for response and demonstrated a 77 percent overall response rate with a 14.5 percent complete remission rate and a 62.9 percent partial response rate (Fischer 2008).

Across the board, the patients with poor prognostic markers experienced good responses (Fischer 2008; [1.2]). My take-home message is that bendamustine/rituximab is effective and feasible for relapsed/refractory, poor-prognosis CLL.

DR SMITH: How would you compare bendamustine to lenalidomide for CLL?

DR SMITH: I believe the data with bendamustine are more mature and solid. Lenalidomide is an exciting drug, but we need to know a little more about how to use it. As a single agent, I believe bendamustine is better in the long term. Combining bendamustine with other drugs is problematic because of myelosuppres-
Dr Osterborg and colleagues reported a trial evaluating ofatumumab, an anti-CD20 monoclonal antibody. The trial enrolled patients with previously treated CLL, who they divided into two broad categories. One group had disease that was refractory to fludarabine and alemtuzumab — the double-refractory (DR) group (59 percent received prior rituximab). Patients in the second group had disease that was refractory to fludarabine, but because of the bulky size of their lymph node enlargement, they were not candidates for alemtuzumab (54 percent received prior rituximab). This was the bulky fludarabine-refractory (BFR) group (Osterborg 2008).

The trial population included 59 patients in the DR group and 79 patients in the BFR group. The overall response rate was close to 50 percent in both groups, and the
median time to the next treatment was approximately nine months across the board in the two arms. The median overall survival was a little more than 14 months (Osterborg 2008).

In summary, ofatumumab is emerging as a “new kid on the block” that is ready to compete with rituximab. The next order of business will be to find out how effective it is for CLL when combined with other agents and to determine the dose that is equivalent to the dose of rituximab. Those issues are currently under investigation.

This is the first positive report with a large sample size, which tells us that ofatumumab is here to stay. We’ll just have to watch the scene.

ADDITIONAL PUBLICATION DISCUSSED


DR CZUCZMAN: This was a Phase II, multicenter, single-agent study of bendamustine for rituximab-refractory, indolent or transformed non-Hodgkin lymphoma (NHL). Patients received 120 mg/m² of bendamustine on days one and two every 21 days. Out of 76 patients enrolled, 74 were evaluable for response. The overall response rate was a respectable 77 percent, including a 34 percent complete response or unconfirmed complete response (CR/CRu) rate. The median duration of response for the responders was 6.7 months. Of interest, patients with indolent lymphoma fared better, with a nine-month median duration of response, whereas those with transformed NHL had a median duration of response of only 2.3 months (Friedberg 2008).

In a Phase II multicenter study in relapsed, indolent B-cell or mantle-
cell lymphoma, patients received bendamustine and rituximab. A 92 percent overall response rate was reported, with a 55 percent CR/CRu rate. The median progression-free survival rate was about two years. This was not a population with rituximab-resistant disease. A significant number of patients (44 percent) were rituximab naïve, and 56 percent had received rituximab but did not have resistant disease (Robinson 2008). The major toxicity was myelosuppression. They used 90 mg/m² of bendamustine on days two and three on a 28-day cycle.

---

**Journal Club Paper**


- **DR LOVE**: John, how do you use bendamustine for NHL and what dose do you use?

- **DR LEONARD**: I believe that it’s a potentially useful drug. I’ve been using it primarily for relapsed follicular lymphoma and for some patients with relapsed CLL or relapsed mantle-cell lymphoma. The dose depends on the situation. I use anywhere from 90 to 120 mg/m² depending on the patient’s bone marrow reserve, age and other factors.

- **DR LOVE**: Myron, what do we know about how rituximab/bendamustine (R-B) compares to R-CHOP?

- **DR CZUCZMAN**: The last two ASH meetings included presentations of the first and second interim analyses of a large German study evaluating R-CHOP versus R-B as first-line therapy for follicular, indolent or mantle-cell lymphoma. According to the data, R-B is not inferior to R-CHOP. These groups of patients had similar overall and complete response rates (Rummel 2008; [2.1]). I don’t believe that we can assess durability of response because it’s still early in the course. I want to see more data and details to understand whether someday we will replace R-CHOP with R-B.

- **DR MOSKOWITZ**: I agree with Myron. It seems almost too good to be true — the equivalency of R-B and R-CHOP and the lack of toxicity with R-B (2.1). I’ll be happy to use it after the results are peer reviewed and reported in a way that demonstrates this equivalency. I am still concerned about long-term side effects of a drug that we don’t know enough about.

Some of the physicians who remember bendamustine from the olden days in Europe are concerned about long-term myelodysplastic syndrome. So I — and others may disagree — will be hard pressed to use bendamustine for a younger patient who may receive a transplant in the future.
This was a Phase II trial of rituximab/bortezomib for patients with relapsed/refractory mantle-cell or follicular lymphoma. The trial enrolled only 23 patients — 10 with follicular and 13 with mantle-cell lymphoma. The median age of the patients was 66. Initially, patients received rituximab and bortezomib. Patients who responded were then to receive maintenance rituximab and bortezomib (Blum 2008).

Investigators reported a reasonable overall response rate of 39 percent, including nine out of 23 patients with a CR/CRu. The median progression-free survival was approximately six months. The combination of rituximab/bortezomib has activity. However, it also brings significant toxicity (Blum 2008).

Of these patients who were previously treated, about 57 percent had Grade III autonomic, sensory or motor neuropathies despite a reduction in the dose of bortezomib from 1.5 to 1.3 mg/m². Because of the neurotoxicity, none of the patients who responded went on to mainte-
DR LOVE: Rick, do you have any comments about bortezomib-related neuropathy?

DR HAGEMEISTER: After a year or so, it seems to resolve completely in the majority of patients who complain of more significant neuropathy. So, fortunately, it eventually does go away.

Journal Club Paper


DR GREGORY: EORTC-20981 was a large Intergroup study with randomization to CHOP versus R-CHOP for patients with relapsed follicular lymphoma who had not received more than two prior treatments or an anthracycline. The results were reported previously, and R-CHOP was superior. Patients who had partial or complete responses were then randomly assigned to observation or maintenance rituximab every three months for two years or until relapse. Progression-free survival was clearly better for the group who received maintenance rituximab, whether they had received CHOP or R-CHOP initially (Van Oers 2006).

At ASH 2008 the long-term follow-up of six years demonstrated that progression-free survival was much improved for the patients who received maintenance rituximab (Van Oers 2008; [2.2]).

### EORTC-20981: Maintenance Rituximab versus Observation for Relapsed/Refractory Follicular Lymphoma Treated with CHOP or R-CHOP as Induction Therapy (Median Follow-Up of Six Years)

<table>
<thead>
<tr>
<th></th>
<th>Maintenance rituximab (n = 167)</th>
<th>Observation (n = 167)</th>
<th>Hazard ratio</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median progression-free survival</td>
<td>3.7 years</td>
<td>1.3 years</td>
<td>0.55</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Five-year overall survival (OS)</td>
<td>74%</td>
<td>64%</td>
<td>—</td>
<td>0.07</td>
</tr>
<tr>
<td>Grade III/IV infection</td>
<td>9.7%</td>
<td>2.4%</td>
<td>—</td>
<td>0.01</td>
</tr>
</tbody>
</table>

DR GREGORY: This was a meta-analysis of five trials in which maintenance rituximab was used (Vidal 2009). Most of these trials enrolled patients who had relapsed follicular lymphoma.

Some of the studies used a rituximab/chemotherapy induction regimen before the maintenance regimen was administered. A couple of the studies used only rituximab as front-line treatment and then maintenance rituximab.

The conclusion was that in the relapsed setting, maintenance rituximab seems to confer an improvement in progression-free and overall survival (Vidal 2009; [2.3]).

DR CZUCZMAN: The meta-analysis included different types of therapies and, therefore, it is difficult to draw conclusions. In the paper by Van Oers, no difference was reported in the five-year overall survival between the two groups, although we saw a significant improvement in progression-free survival (Van Oers 2008).

However, restaging practices were not standardized.

During the time that maintenance rituximab was administered, each institution followed individual standards. So not every patient received a scan at six months or one year, which is problematic when using progression-free survival as an endpoint.

2.3 Meta-Analysis of Trials Evaluating Maintenance Rituximab for Relapsed/Refractory Follicular Lymphoma

“Five trials including 1143 adult patients were included in this meta-analysis. Data for 985 patients with follicular lymphoma were available for the meta-analysis of overall survival. Patients treated with maintenance rituximab had statistically significantly better overall survival than patients in the observation arm or patients treated at relapse (hazard ratio [HR] for death = 0.60, 95% confidence interval [CI] = 0.45 to 0.79). The rate of infection-related adverse events was higher with rituximab maintenance treatment (HR = 1.99, 95% CI = 1.21 to 3.27). Patients with refractory or relapsed (ie, previously treated) follicular lymphoma had a survival benefit with maintenance rituximab therapy (HR for death = 0.58, 95% CI = 0.42 to 0.79), whereas previously untreated patients did not (HR for death = 0.68, 95% CI = 0.37 to 1.25). Conclusions: These results suggest that maintenance therapy with rituximab, either as four weekly infusions every 6 months or as a single infusion every 2–3 months, should be added to standard therapy for patients with relapsed or refractory (ie, previously treated) follicular lymphoma after successful induction therapy. The higher rate of infections with rituximab therapy should be taken into consideration when making treatment decisions.”

DR LEONARD: A subset analysis from a previous Phase II study with lenalidomide demonstrated a 19 percent response rate for recurrent diffuse large B-cell lymphoma (DLBCL; [Wiernik 2008]).

The study by Dr Czuczman was an international, confirmatory, follow-up study with 73 patients who had recurrent DLBCL. The patients’ median age was 67, and they had received a median of three prior regimens (Czuczman 2008).

The overall response rate of 29 percent is comparable to what we’re starting to observe in other subtypes of lymphoma. These were mostly partial responses. An additional 15 percent of the patients had stable disease. The main toxicities were neutropenia, thrombocytopenia and anemia (Czuczman 2008).

These results suggest that lenalidomide is an active drug. The question will be how to integrate lenalidomide in the management of DLBCL. Concurrent use with chemotherapy will be complicated by cytopenias. I don’t believe we will use it at the same time as chemotherapy, although that approach is being evaluated.

I believe we will see more studies evaluating chemotherapy followed by a lenalidomide-based regimen as maintenance.

ADDITIONAL PUBLICATIONS DISCUSSED


Diffuse Large B-Cell Lymphoma (DLBCL)

Journal Club Paper


**Journal Club Paper**


> **DR MOSKOWITZ:** We’re all hoping that lenalidomide is a drug we can use and use safely. Consider a patient who is ineligible for a transplant and in his or her midseventies who receives R-CHOP and experiences a relapse 18 months later.

I would predict that oncologists would use lenalidomide/rituximab as their first choice once these results are published. It’s easy to administer with no significant downside — you can always use intravenous chemotherapy thereafter.

> **DR MOSKOWITZ:** This paper was an attempt to evaluate subsets of patients in a Phase II trial who received dose-adjusted EPOCH-R for previously untreated DLBCL and also to analyze the data based on the International Prognostic Index. About three fourths of the patients had not experienced disease progression and were alive at five years (Wilson 2008).

Of the patients with low-risk or low-intermediate-risk disease, more than 90 percent were event free. However, for patients with multiple risk factors, no benefit was evident with this treatment program compared to standard R-CHOP-21, with fewer than half of the patients being free of disease progression (Wilson 2008).

Evaluating the data on MIB-1 revealed no difference in outcome. The best marker for efficacy with dose-adjusted EPOCH-R was Bcl-6 expression. Those patients with Bcl-6-positive disease fared extremely well. Of the minority of patients

---

### 3.1 Phase III Study Comparing R-CHOP to EPOCH-R

**Protocol IDs:** CALGB-50303, ECOG-50303, NCI-05-C-0252, NCT00118209  
**Target Accrual:** 478

![R-CHOP q21d x 6 cycles](image)

![EPOCH-R + filgrastim q21d x 6 cycles](image)

**Eligibility**

Previously untreated de novo diffuse large B-cell NHL

**Study Contacts**

*Cancer and Leukemia Group B*  
Wyndham Wilson, MD  
Tel: 301-435-2415

Andrew Zelenetz, MD  
Tel: 212-639-2656

**SOURCE:** NCI Physician Data Query, July 2009.
with Bcl-6-negative disease, only half were event free (Wilson 2008).

▸ DR MOSKOWITZ: This presentation makes an assumption, which I believe is without basis, that R-CHOP-14 is superior to R-CHOP-21 for DLBCL. The investigators decided to use DENSE-R-CHOP-14. The rationale is that it usually takes three to four cycles to attain an active serum concentration of rituximab, which this group believes is necessary (Reiser 2006).

Pharmacokinetic data suggested that when intensified rituximab was used in the first few cycles, a quick peak was obtained in the serum rituximab concentration and then maintained at a certain level throughout the treatment program (Poeschel 2006). This may have an effect on outcome.

Instead of using R-CHOP-14, with eight doses of rituximab, these investigators used DENSE–R-CHOP-14, with 12 doses of rituximab, for a group of elderly patients in a Phase II design. Adequate serum rituximab levels were maintained with this treatment program. The results were compared to the results with R-CHOP-14 from the RICOVER trial (Pfreundschuh 2008).

DENSE-R-CHOP-14 was more toxic than R-CHOP-14 and, similarly to R-CHOP-14, it required antibiotic prophylaxis. A significant amount of morbidity was recorded among the first 25 patients.

Among patients with low-risk or low-intermediate-risk disease, no difference was apparent between DENSE-R-CHOP-14 and R-CHOP-14. Patients with multiple risk factors, however, had an improved event-free survival with DENSE-R-CHOP-14 (Pfreundschuh 2008; [3.2]).

I would caution community physicians about using this until we find out whether in fact R-CHOP-14 is superior to R-CHOP-21, because this is a toxic treatment program for the elderly. I’d be careful about using it in that particular patient population.

▸ DR LEONARD: I believe this is an interesting report, but you have to remember that it’s a single-institution, 70-patient study with many retrospective subset analyses. I would emphasize the importance of the ongoing randomized study comparing CHOP-R to EPOCH-R (CALGB-50303; [3.1]), which is a prospective analysis of approximately 400 patients with gene expression profiling.

Journal Club Paper

“Despite a less favorable study population DENSE-R-CHOP-14 resulted in a somewhat higher CR (83% vs 78%) and lower progression under therapy rate (5% vs 7%) rate, but event free and overall survival were not different compared to 8 biweekly applications of R.

However, a subgroup analysis of patients according to IPI risk group showed that DENSE-R-CHOP-14 resulted in a higher complete response rate of patients with poor-prognosis (IPI:3-5) disease (81% vs 68%) and in a better 1-year event-free survival rate (74% vs 65%) of these patients.”


ADDITIONAL PUBLICATIONS DISCUSSED


Reiser M et al. Serum levels and pharmacokinetic of rituximab in bi-weekly R-CHOP in elderly patients with DLBCL treated in the RICOVER-60 trial. Proc ASH 2006; Abstract 2748.


Mantle-Cell Lymphoma

Journal Club Paper


DR SMITH: This international study evaluated lenalidomide for patients with relapsed or refractory mantle-cell lymphoma. These patients had heavily pretreated disease: Patients had received a median of three prior treatments, and one fourth had received bortezomib.

Lenalidomide was administered daily, three weeks on, one week off, at 25 milligrams until either disease progression or toxicity. The overall response rate was 41 percent, including 13 percent CR/CRu and 28 percent partial responses (Zinzani 2008; [4.1]). Lenalidomide is active as a single agent in this heavily pretreated population. It was well tolerated, although some myelosuppression occurred, as you’d expect.
We’d like to achieve better results ultimately by perhaps evaluating lenalidomide in combination with other agents, but right now I believe that lenalidomide is a reasonable treatment to consider for relapsed mantle-cell lymphoma.

### 4.1 NHL-003: Efficacy and Safety of Lenalidomide Oral Monotherapy for Patients with Relapsed or Refractory Mantle-Cell Lymphoma (MCL)

<table>
<thead>
<tr>
<th>Efficacy</th>
<th>Lenalidomide (n = 39)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall response rate</td>
<td>41%</td>
</tr>
<tr>
<td>Complete response (CR)/unconfirmed CR</td>
<td>13%</td>
</tr>
<tr>
<td>Partial response</td>
<td>28%</td>
</tr>
<tr>
<td><strong>Adverse events (Grade III/IV)</strong></td>
<td></td>
</tr>
<tr>
<td>Neutropenia</td>
<td>51%</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>25%</td>
</tr>
<tr>
<td>Anemia</td>
<td>13%</td>
</tr>
<tr>
<td>Fatigue</td>
<td>10%</td>
</tr>
<tr>
<td>Febrile neutropenia</td>
<td>10%</td>
</tr>
</tbody>
</table>

**SOURCE:** Zinzani PL et al. *Proc ASH* 2008; Abstract 262.

### Journal Club Paper

O’Connor O et al. *Schedule of bortezomib administration may be an important determinant of single-agent activity in patients with relapsed or refractory follicular (FL) lymphoma and mantle cell lymphoma (MCL).* *Proc ASCO* 2007; Abstract 8051.

- **DR SMITH:** The bortezomib dosing question is interesting. From the myeloma standpoint, we administer it twice a week for two weeks, and some data evaluating rituximab/bortezomib reported that once-weekly bortezomib appeared to offer similar efficacy to twice-weekly bortezomib (De Vos 2006). Some of us tend to extrapolate that as, “You can administer it once a week at a little higher dose and do just as well, and it’s easier for the patient.”

- The group at Memorial Sloan-Kettering had reported on a twice-weekly bortezomib schedule (O’Connor 2005), and in this study they used a once-weekly schedule. They reported that weekly dosing with bortezomib may not be as effective as twice weekly for patients with relapsed or refractory follicular lymphoma or mantle-cell lymphoma (O’Connor 2007; [4.2]), suggesting that as a single agent, bortezomib twice a week may be better than once a week.
DR HAGEMEISTER: Dr Negro-Vilar reported at ASCO 2008 on the efficacy and safety of denileukin diftitox in the treatment of CTCL. This report was an analysis involving patients receiving denileukin diftitox in three different trials.

The first trial included patients with CD25-positive, Stage IB through Stage IVA disease treated with nine μg/kg of denileukin diftitox for five days or 18 μg/kg for five days. The second was a three-arm study evaluating the same schedules of treatment versus placebo for patients with CD25-positive Stage IA through Stage III disease who’d received three or fewer prior treatments — a little earlier than the first trial. The third study...
evaluated denileukin diftitox at 18 μg/kg for patients with CD25-positive disease that responded on previous trials and patients with CD25-negative, previously untreated disease.

Not surprisingly, overall, patients who received denileukin diftitox always fared better than patients who received placebo (Negro-Vilar 2008; [5.1]).

A question that was not addressed was that of the correct dose. It appeared to me that patients receiving the higher dose probably fared better as far as overall response was concerned. Also, patients with CD25-positive CTCL fared better than those with CD25-negative disease, although patients with CD25-negative disease still demonstrated responses (5.1).

The package insert states that patients must have CD25-positive disease, but these data indicate patient responses to denileukin diftitox independent of CD25 status.

I believe that the most important toxicity factor is that of capillary leaks requiring discontinuation of the drug. This occurred in only three percent of the patients.

The authors didn’t report the overall risk of capillary leak or the severity in this entire set of trials. Grade III to Grade IV capillary leaks occurred in six percent of the patients, but only three percent discontinued therapy.

DR GREGORY: I’ve had success using denileukin diftitox earlier for patients with CTCL who were referred to me by dermatologists after standard treatments had failed. Patients with heavily pretreated disease don’t tolerate this drug well.

### 5.1

**Efficacy and Safety of Denileukin Diftitox (Dd) in Patients with CTCL: An Integrated Analysis of Three Phase III Trials**

<table>
<thead>
<tr>
<th>Efficacy</th>
<th>Dd treated (all) n = 263</th>
<th>Dd HD CD25+ n = 118</th>
<th>Dd HD CD25- n = 36</th>
<th>Placebo n = 44</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median PFS</td>
<td>794 days*</td>
<td>870 days*</td>
<td>&gt;487 days*</td>
<td>124 days</td>
</tr>
<tr>
<td>ORR</td>
<td>38.0%*</td>
<td>47.5%*</td>
<td>30.6%</td>
<td>15.9%</td>
</tr>
<tr>
<td>CR/CCR</td>
<td>9.1%</td>
<td>11.0%</td>
<td>8.3%</td>
<td>2.3%</td>
</tr>
<tr>
<td>PR</td>
<td>28.9%</td>
<td>36.4%</td>
<td>22.2%</td>
<td>13.6%</td>
</tr>
<tr>
<td>PD</td>
<td>17.5%</td>
<td>11.0%</td>
<td>25.0%</td>
<td>52.3%</td>
</tr>
</tbody>
</table>

* p < 0.02 or better compared to placebo

HD = high dose; PFS = progression-free survival; ORR = overall response rate; CR = complete response; CCR = clinical complete response; PR = partial response; PD = progressive disease


**ADDITIONAL PUBLICATION DISCUSSED**

POST-TEST

Integrating Emerging Clinical Research into the Practical Management of Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia — Issue 1, 2009

QUESTIONS (PLEASE CIRCLE ANSWER):

1. A trial of bendamustine/rituximab for relapsed or refractory CLL demonstrated an overall response rate of _________.
   a. 77 percent
   b. 57 percent
   c. 37 percent
   d. None of the above

2. A trial of bendamustine alone for rituximab-refractory indolent or transformed NHL demonstrated an overall response rate of _________.
   a. 77 percent
   b. 57 percent
   c. 37 percent
   d. None of the above

3. A trial of bendamustine/rituximab for relapsed or refractory indolent B-cell or mantle-cell lymphoma demonstrated an overall response rate of _________.
   a. 92 percent
   b. 52 percent
   c. 32 percent
   d. None of the above

4. Early results from a Phase III randomized trial comparing bendamustine/rituximab to R-CHOP as first-line therapy for follicular, indolent or mantle-cell lymphoma demonstrated that the two regimens have similar overall response rates.
   a. True
   b. False

5. Pulini and colleagues reported an overall response rate of ________ for patients with primary cutaneous lymphoma treated with pegylated liposomal doxorubicin.
   a. 45 percent
   b. 68 percent
   c. 81 percent

6. A meta-analysis of maintenance rituximab was evaluated in relapsed disease and concluded that maintenance rituximab after successful induction therapy improves ________ for relapsed follicular lymphoma.
   a. Progression-free survival
   b. Overall survival
   c. Both a and b

7. The NHL-003 study reported an overall response rate of ________ with lenalidomide oral monotherapy for patients with relapsed or refractory mantle-cell lymphoma.
   a. 15 percent
   b. 25 percent
   c. 41 percent
   d. 52 percent

8. In a Memorial Sloan-Kettering Cancer Center study for patients with relapsed or refractory mantle cell or follicular lymphoma, weekly dosing with bortezomib appeared to be as effective as twice-weekly dosing.
   a. True
   b. False

9. EORTC-20981, which evaluated maintenance rituximab versus observation following induction with CHOP or R-CHOP for relapsed/refractory follicular lymphoma, demonstrated that maintenance rituximab improves _________.
   a. Progression-free survival
   b. Overall survival
   c. Both a and b

10. An integrated analysis of three large Phase III trials evaluating efficacy and safety of denileukin diftitox (Dd) in patients with CTCL reported an overall response rate of ________ with Dd compared to placebo.
    a. 15 percent
    b. 23 percent
    c. 38 percent
    d. 49 percent

Post-test answer key: 1a, 2a, 3a, 4a, 5c, 6c, 7c, 8b, 9a, 10c
PART ONE — Please tell us about your experience with this educational activity

Was the activity evidence based, fair, balanced and free from commercial bias?
☐ Yes ☐ No
If no, please explain:

Will this activity help you improve patient care?
☐ Yes ☐ No ☐ Not applicable
If no, please explain:

Did the activity meet your educational needs and expectations?
☐ Yes ☐ No
If no, please explain:

Please respond to the following learning objectives (LOs) by circling the appropriate selection:

As a result of this activity, I will be able to:
- Develop an algorithm for the evaluation and treatment of newly diagnosed or relapsed/refractory chronic lymphocytic leukemia. .............................................. 4 3 2 1 N/M N/A
- Apply the results of emerging research to effectively and safely integrate novel agents and regimens into the management of relapsed/refractory indolent lymphoma. .............................................. 4 3 2 1 N/M N/A
- Counsel patients with follicular lymphoma about the risks and benefits associated with maintenance therapy. .............................................. 4 3 2 1 N/M N/A
- Assess the utility of clinical and molecular biomarkers in the selection of first-line therapy for diffuse large B-cell lymphoma (DLBCL) .............................................. 4 3 2 1 N/M N/A
- Identify investigational agents under evaluation for relapsed/refractory DLBCL .............................................. 4 3 2 1 N/M N/A
- Communicate the existing and emerging roles of proteasome inhibitors and IMiDs® to patients with mantle-cell lymphomas. .............................................. 4 3 2 1 N/M N/A
- Integrate currently available therapeutic strategies into the management of advanced cutaneous T-cell lymphoma. .............................................. 4 3 2 1 N/M N/A

How would you characterize your level of knowledge on the following topics?

4 = Excellent 3 = Good 2 = Adequate 1 = Suboptimal

BEFORE AFTER

Activity of bendamustine for relapsed/refractory chronic lymphocytic leukemia (CLL) or indolent lymphoma
4 3 2 1 4 3 2 1

Efficacy of ofatumumab for relapsed/refractory CLL
4 3 2 1 4 3 2 1

Maintenance rituximab following CHOP or R-CHOP for relapsed/refractory follicular lymphoma
4 3 2 1 4 3 2 1

Activity of fostamatinib or lenalidomide for relapsed/refractory diffuse large B-cell lymphoma
4 3 2 1 4 3 2 1

Dose and schedule of bortezomib for relapsed/refractory lymphoma
4 3 2 1 4 3 2 1

Denileukin diftitox for cutaneous T-cell lymphoma
4 3 2 1 4 3 2 1
What other practice changes will you make or consider making as a result of this activity?

What additional information or training do you need on the activity topics or other oncology-related topics?

Additional comments about this activity:

As part of our ongoing, continuous quality-improvement effort, we conduct postactivity follow-up surveys to assess the impact of our educational interventions on professional practice. Please indicate your willingness to participate in such a survey.

☐ Yes, I am willing to participate in a follow-up survey.
☐ No, I am not willing to participate in a follow-up survey.

PART TWO — Please tell us about the faculty and moderator for this educational activity

<table>
<thead>
<tr>
<th>Faculty Name</th>
<th>Knowledge of subject matter</th>
<th>Effectiveness as an educator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Myron S Czuczman, MD</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
<tr>
<td>Stephanie A Gregory, MD</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
<tr>
<td>Fredrick B Hagemeister, MD</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
<tr>
<td>John P Leonard, MD</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
<tr>
<td>Vicki A Morrison, MD</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
<tr>
<td>Craig Moskowitz, MD</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
<tr>
<td>Kanti R Rai, MD</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
<tr>
<td>Mitchell R Smith, MD, PhD</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
<tr>
<td>Moderator</td>
<td>Knowledge of subject matter</td>
<td>Effectiveness as an educator</td>
</tr>
<tr>
<td>Neil Love, MD</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
</tbody>
</table>

Please recommend additional faculty for future activities:

Other comments about the faculty and moderator for this activity:

REQUEST FOR CREDIT — Please print clearly

Name: ................................................................. Specialty: .................................................................
Professional Designation:
☐ MD ☐ DO ☐ PharmD ☐ NP ☐ RN ☐ PA ☐ Other .................................................................
Medical License/ME Number: ................................................................. Last 4 Digits of SSN (required): .................................................................
Street Address: ................................................................. Box/Suite: .................................................................
City, State, Zip: .................................................................
Telephone: ................................................................. Fax: .................................................................
Email: .................................................................
Research To Practice designates this educational activity for a maximum of 3.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
I certify my actual time spent to complete this educational activity to be _________ hour(s).
Signature: ................................................................. Date: .................................................................

To obtain a certificate of completion and receive credit for this activity, please complete the Post-test, fill out the Educational Assessment and Credit Form and fax both to (800) 447-4310, or mail both to Research To Practice, One Biscayne Tower, 2 South Biscayne Boulevard, Suite 3600, Miami, FL 33131. You may also complete the Post-test and Educational Assessment online at CME.ResearchToPractice.com.
The compact discs, Internet content and accompanying printed material are protected by copyright. No part of this program may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or utilizing any information storage and retrieval system, without written permission from the copyright owner.

The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information and comparison with recommendations of other authorities.